Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Studie zur gleichzeitigen Verabreichung eines experimentellen Lebendimpfstoffs gegen das Respiratory Syncytial Virus bei Säuglingen und Kleinkindern (CORAL)

15. September 2026 aktualisiert von: Sanofi Pasteur, a Sanofi Company

Phase III, randomisierte, einfach blinde, placebokontrollierte, multizentrische Studie zur Bewertung der Nichtbeeinträchtigung der gleichzeitigen Verabreichung routinemäßiger pädiatrischer Impfstoffe auf die Antikörperreaktion eines in der Untersuchung befindlichen Lebendimpfstoffs gegen das Respiratory Syncytial Virus (RSV) bei gesunden Säuglingen und Kleinkinder (CORAL)

This study is a Phase III, randomized, single-blind, placebo-controlled, multi-center study to be conducted in healthy infants and toddlers which will be enrolled at approximately 6 months of age (Cohort 1) and approximately 12 months of age (Cohort 2). The primary objective of the study will be to assess non-inferiority of the RSV infant and toddler (RSVt) vaccine antibody response when administered concomitantly with routine pediatric vaccines at 6 months of age (Diphtheria and Tetanus Toxoids and Acellular Pertussis, Inactivated Poliovirus, Haemophilus b Conjugate and Hepatitis B Vaccine [Vaxelis® or Pentacel® and Recombivax HB®] Prevnar 20®, and RotaTeq®), and 12 months of age (M-M-R II, VARIVAX, and Prevnar 20 or per local country recommendations) compared to when administered non-concomitantly.

Studienübersicht

Status

Beendet

Bedingungen

Intervention / Behandlung

Detaillierte Beschreibung

The study duration is approximately 9 months for each participant.

  • Cohort 1: Visits at 6, 7, and 8 and 9 months of age for both groups with visit at 10 months of age for Group 2 only
  • Cohort 2: Visits at 12, 13, 14 and 15 months of age for both groups with visit at 16 months of age for Group 4 only
  • Routine pediatric vaccines (authorized auxiliary medicinal products (AxMP) will be administered at 6 months in Cohort 1 and 12 months of age in Cohort 2, as per Advisory Committee on Immunization Practice (ACIP) or local country recommendations.

Studientyp

Interventionell

Einschreibung (Tatsächlich)

2226

Phase

  • Phase 3

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

      • Mexico City, Mexiko, 06760
        • Investigational Site Number : 4840004
    • Mexico City
      • Mexico City, Mexico City, Mexiko, 04530
        • Investigational Site Number : 4840001
    • Morelos
      • Temixco, Morelos, Mexiko, 62587
        • Investigational Site Number : 4840002
      • Caguas, Puerto Rico, 00725
        • Investigational Site Number : 6300001
      • Ponce, Puerto Rico, 00716
        • Investigational Site Number : 6300003
      • Trujillo Alto, Puerto Rico, 00976
        • Investigational Site Number : 6300004
    • Alabama
      • Birmingham, Alabama, Vereinigte Staaten, 35205
        • Alabama Clinical Therapeutics - Birmingham - St. Vincent's Drive- Site Number : 8400007
      • Grand Bay, Alabama, Vereinigte Staaten, 36541
        • South Alabama Medical Clinic- Site Number : 8400065
      • Mobile, Alabama, Vereinigte Staaten, 36608
        • MedPharmics - Mobile - Dauphin Street- Site Number : 8400017
    • Arkansas
      • Fayetteville, Arkansas, Vereinigte Staaten, 72703
        • Northwest Arkansas Pediatric Clinic- Site Number : 8400002
    • California
      • Bell Gardens, California, Vereinigte Staaten, 90201
        • Alliance Research Institute - Bell Gardens - Garfield Avenue- Site Number : 8400040
      • Huntington Park, California, Vereinigte Staaten, 90255
        • Matrix Clinical Research - Huntington Park- Site Number : 8400018
      • La Mesa, California, Vereinigte Staaten, 91942
        • Paradigm Clinical Research Centers- Site Number : 8400059
      • Los Angeles, California, Vereinigte Staaten, 90057
        • Matrix Clinical Research - Los Angeles- Site Number : 8400008
      • Oakland, California, Vereinigte Staaten, 94611
        • Kaiser Permanente - Oakland Medical Center- Site Number : 8400047
      • Palo Alto, California, Vereinigte Staaten, 94304
        • Stanford University Medical Center CTRU - 800 Welch Road- Site Number : 8400070
      • Roseville, California, Vereinigte Staaten, 95661
        • Kaiser Permanente - Sierra Gardens- Site Number : 8400063
      • Sacramento, California, Vereinigte Staaten, 95815
        • Kaiser Permanente - Point West Medical Offices- Site Number : 8400064
      • San Jose, California, Vereinigte Staaten, 95119
        • Kaiser Permanente - San Jose Medical Center- Site Number : 8400060
      • Santa Clara, California, Vereinigte Staaten, 95051
        • Kaiser Permanente - Santa Clara Medical Center- Site Number : 8400061
      • Sherman Oaks, California, Vereinigte Staaten, 91356-4173
        • Integrated Clinical Research LLC- Site Number : 8400036
      • Walnut Creek, California, Vereinigte Staaten, 94596
        • Kaiser Permanente - Walnut Creek Medical Center- Site Number : 8400062
    • District of Columbia
      • Washington D.C., District of Columbia, Vereinigte Staaten, 20016
        • Velocity Clinical Research - Washington DC- Site Number : 8400050
    • Florida
      • Doral, Florida, Vereinigte Staaten, 33166
        • Prohealth Research Center- Site Number : 8400068
      • Hollywood, Florida, Vereinigte Staaten, 33021
        • The Medici Medical Research- Site Number : 8400055
      • Miami, Florida, Vereinigte Staaten, 33126
        • Dade Research Center- Site Number : 8400014
      • Miami Lakes, Florida, Vereinigte Staaten, 33014
        • Riveldi Biomedical Research and Associates - Miami Lakes- Site Number : 8400015
      • Pensacola, Florida, Vereinigte Staaten, 32501
        • SEC Clinical Research - Pensacola- Site Number : 8400034
      • Tampa, Florida, Vereinigte Staaten, 33613
        • PAS Research- Site Number : 8400005
    • Idaho
      • Idaho Falls, Idaho, Vereinigte Staaten, 83404
        • Leavitt Women's Healthcare- Site Number : 8400009
    • Iowa
      • Sioux City, Iowa, Vereinigte Staaten, 51106
        • Velocity Clinical Research - Sioux City- Site Number : 8400054
    • Kansas
      • El Dorado, Kansas, Vereinigte Staaten, 67042
        • Alliance for Multispeciality Research - El Dorado- Site Number : 8400019
    • Kentucky
      • Lexington, Kentucky, Vereinigte Staaten, 40536
        • University of Kentucky Chandler Medical Center- Site Number : 8400051
    • Louisiana
      • New Orleans, Louisiana, Vereinigte Staaten, 70119
        • Velocity Clinical Research - New Orleans- Site Number : 8400058
      • New Orleans, Louisiana, Vereinigte Staaten, 70125
        • Research Works INC- Site Number : 8400044
    • Mississippi
      • Gulfport, Mississippi, Vereinigte Staaten, 39503
        • Velocity Clinical Research - Gulfport- Site Number : 8400011
    • Missouri
      • Springfield, Missouri, Vereinigte Staaten, 65802
        • QPS Bio-Kinetic Clinical Applications- Site Number : 8400046
    • Montana
      • Great Falls, Montana, Vereinigte Staaten, 59405
        • Boeson Research - Great Falls- Site Number : 8400041
      • Missoula, Montana, Vereinigte Staaten, 59804
        • Boeson Research - Missoula- Site Number : 8400006
    • Nebraska
      • Grand Island, Nebraska, Vereinigte Staaten, 68803
        • Velocity Clinical Research - Grand Island- Site Number : 8400016
      • Lincoln, Nebraska, Vereinigte Staaten, 68516
        • Midwest Childrens Health Research Institute- Site Number : 8400038
      • Omaha, Nebraska, Vereinigte Staaten, 68134
        • Velocity Clinical Research - Omaha- Site Number : 8400001
    • Nevada
      • Henderson, Nevada, Vereinigte Staaten, 89014
        • PAS Research - Henderson- Site Number : 8400049
    • New York
      • Garden City, New York, Vereinigte Staaten, 11530
        • NYU Langone Cardiothoracic Surgery Associates - Garden City- Site Number : 8400048
      • Liverpool, New York, Vereinigte Staaten, 13088
        • Summerwood Pediatrics- Site Number : 8400021
      • Syracuse, New York, Vereinigte Staaten, 13210
        • SUNY Upstate Medical University - Syracuse- Site Number : 8400029
    • Ohio
      • Dayton, Ohio, Vereinigte Staaten, 45414
        • Ohio Pediatrics - Dayton- Site Number : 8400033
      • Dayton, Ohio, Vereinigte Staaten, 45409
        • Dayton Clinical Research- Site Number : 8400030
      • South Euclid, Ohio, Vereinigte Staaten, 44121
        • Senders Pediatrics- Site Number : 8400022
    • Oregon
      • Gresham, Oregon, Vereinigte Staaten, 97030
        • Cyn3rgy Research- Site Number : 8400053
    • Pennsylvania
      • Erie, Pennsylvania, Vereinigte Staaten, 16506
        • Square-1 Clinical Research- Site Number : 8400031
      • Pittsburgh, Pennsylvania, Vereinigte Staaten, 15227
        • Pas Research - Pittsburgh- Site Number : 8400043
    • South Carolina
      • Charleston, South Carolina, Vereinigte Staaten, 29407
        • Neighbors Pediatrics- Site Number : 8400072
      • Greenville, South Carolina, Vereinigte Staaten, 29607
        • Tribe Clinical Research - Greenville - Verdae Boulevard- Site Number : 8400012
    • Texas
      • Corpus Christi, Texas, Vereinigte Staaten, 78413
        • South Texas Clinical Research- Site Number : 8400004
      • Dallas, Texas, Vereinigte Staaten, 75230
        • Javara - Privia Medical Group North Texas - Dallas- Site Number : 8400003
      • Edinburg, Texas, Vereinigte Staaten, 78539
        • PAS Research - Children's Care Clinic- Site Number : 8400035
      • Fort Worth, Texas, Vereinigte Staaten, 76104
        • Helios Clinical Research - Fort Worth - 8th Avenue- Site Number : 8400020
      • Houston, Texas, Vereinigte Staaten, 77008
        • Ventavia Research Group - Houston - North Loop West- Site Number : 8400010
      • Houston, Texas, Vereinigte Staaten, 77065
        • DM Clinical Research - Houston - Jones Road- Site Number : 8400052
      • Houston, Texas, Vereinigte Staaten, 77070
        • Mercury Clinical Research - Houston - Savoy Drive- Site Number : 8400045
      • Houston, Texas, Vereinigte Staaten, 77090
        • Houston Clinical Research Associates- Site Number : 8400013
      • Houston, Texas, Vereinigte Staaten, 77030
        • The University of Texas Health Science Center- Site Number : 8400037
      • Houston, Texas, Vereinigte Staaten, 77071
        • La Providence Pediatrics & Family Clinics- Site Number : 8400039
      • League City, Texas, Vereinigte Staaten, 77555
        • University of Texas Medical Branch at Galveston- Site Number : 8400057
      • League City, Texas, Vereinigte Staaten, 77573
        • Maximos Ob/Gyn- Site Number : 8400024
      • Plano, Texas, Vereinigte Staaten, 75093
        • Research Your Health- Site Number : 8400066
      • Richmond, Texas, Vereinigte Staaten, 77469
        • Pediatric Center - Richmond- Site Number : 8400032
      • Tomball, Texas, Vereinigte Staaten, 77375
        • North Houston Internal Medicine & Pediatric Clinic- Site Number : 8400025
    • Utah
      • Orem, Utah, Vereinigte Staaten, 84057
        • Utah Valley Pediatrics - Orem- Site Number : 8400067
      • Pleasant View, Utah, Vereinigte Staaten, 84404
        • Ogden Clinic - Mountain View - CCT Research- Site Number : 8400056
      • Roy, Utah, Vereinigte Staaten, 84067
        • Wee Care Pediatrics - Roy- Site Number : 8400071

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

6 Monate bis 1 Jahr (Kind)

Akzeptiert gesunde Freiwillige

Ja

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  • Aged 6 months for Cohort 1 and 12 months for Cohort 2 on the day of inclusion ("6 months" means from the day of the 6-month birthday to the day before the 7-month birthday and "12 months" means from the day of the 12-month birthday to the day before the 13-month birthday)
  • Participants who are healthy as determined by medical evaluation including medical history and physical examination
  • For Cohort 1: Infant received doses of vaccines containing hepatitis B, diphtheria, tetanus, pertussis, Haemophilus influenzae type B (Hib), and inactivated poliovirus vaccine (IPV) antigens, with Advisory Committee on Immunization Practice (ACIP) recommended vaccines. The last dose(s) of these vaccines must be at least 28 days before the first study visit
  • Infant received the recommended doses of a recommended pneumococcal conjugate vaccine (as per local schedule) at least 28 days before the first study visit.

Exclusion Criteria:

  • Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months)
  • Known previous infection with diphtheria, tetanus, Hib, measles, mumps, rubella, rotavirus, pneumococcus, polio, hepatitis B virus
  • Known systemic hypersensitivity to any of the study intervention components, or history of a life-threatening reaction to the study intervention used in the study or to a product containing any of the same substances
  • Chronic illness that, in the opinion of the investigator, is at a stage where it might interfere with study conduct or completion
  • History of medically diagnosed wheezing
  • Any acute febrile illness in the past 48 hours that according to investigator judgment is significant enough to interfere with successful inoculation on the day of vaccination. A prospective participant should not be included in the study until the condition has resolved or the febrile event has subsided.
  • Probable or confirmed ongoing case of viral respiratory infection (including COVID 19, influenza, rhinovirus, etc.) at the time of enrollment. A prospective participant should not be included in the study until the respiratory infection has resolved.
  • Member of a household that contains an immunocompromised individual, including, but not limited to:
  • A person living with human immunodeficiency virus (HIV)
  • A person who has received chemotherapy within the 12 months prior to study enrollment
  • A person who has received (within the past 6 months) or is receiving (at the time of enrollment) immunosuppressant agents
  • A person living with a solid organ or bone marrow transplant
  • Potential close contact with other immunocompromised individual within 30 days after each vaccination as per investigator's discretion
  • History of definitive contraindications to any of the concomitant vaccines that will be administered as part of the study protocol
  • Participant's biological mother with previous receipt or planned administration of an investigational RSV vaccine during pregnancy and/or breastfeeding
  • Receipt of any vaccine in the 4 weeks preceding RSVt vaccine administration or planned receipt of any vaccine outside of study protocol in the 4 weeks following RSVt vaccine administration, except for influenza and/or COVID-19 vaccination, which may be received at least 1 week before or 1 week after RSVt vaccine administration
  • Previous receipt of an investigational RSV vaccine or receiving any anti RSV product (such as ribavirin or RSV immune globulin) at the time of enrollment
  • Receipt of immune globulins, blood or blood-derived products in the past 3 months
  • Receipt of intranasal and intra-ocular medications within 3 days prior to study enrollment
  • Previous receipt of an RSV monoclonal antibody within 6 months prior to the first study vaccine administration or planned receipt for duration of the study
  • For Cohort 1: Prior receipt of routine 6-month pediatric vaccine doses (as per local schedule)
  • For Cohort 2: Prior receipt of routine 12-month pediatric vaccine doses (as per local schedule)
  • Participation at the time of study enrollment (or in the 6 weeks preceding the first study intervention administration) or planned participation during the present study period in another clinical study investigating a vaccine, drug, medical device, or medical procedure

Note: The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Verhütung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Verdreifachen

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Cohort 1: Group 1- (RSVt vaccine concomitantly at 6 months)

Participants will be administered RSVt vaccine concomitantly with routine pediatric vaccines, 2 doses, at age 6 months. Vaccines administered at age 6 months: RSVt Vaxelis or Pentacel and Recombivax HB, Prevnar 20, and RotaTeq. Placebo will be administered non-concomitantly at 7 months of age

Pharmaceutical form:Liquid for nasal spray-Route of administration:Intranasal

Andere Namen:
  • 534

Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular

Andere Namen:
  • Vaxelis®

Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular

Andere Namen:
  • Pentacel®

Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular

Andere Namen:
  • RECOMBIVAX HB® oder alternativer monovalenter Hepatitis-B-Impfstoff

Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular

Andere Namen:
  • PREVNAR 20®

Pharmaceutical form:Oral solution-Route of administration:Oral

Andere Namen:
  • RotaTeq®

Pharmaceutical form:Liquid for nasal spray-Route of administration:Intranasal

Experimental: Cohort 1: Group 2- (RSVt vaccine non-concomitantly at 7 months)

Participants will be administered RSVt vaccine non-concomitantly with routine pediatric vaccines, 2 doses, at age 7 months. Vaccines administered at age 6 months: Vaxelis or Pentacel and Recombivax HB, Prevnar 20, and RotaTeq. Placebo will be administered concomitantly at 6 months of age

Pharmaceutical form:Liquid for nasal spray-Route of administration:Intranasal

Andere Namen:
  • 534

Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular

Andere Namen:
  • Vaxelis®

Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular

Andere Namen:
  • Pentacel®

Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular

Andere Namen:
  • RECOMBIVAX HB® oder alternativer monovalenter Hepatitis-B-Impfstoff

Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular

Andere Namen:
  • PREVNAR 20®

Pharmaceutical form:Oral solution-Route of administration:Oral

Andere Namen:
  • RotaTeq®

Pharmaceutical form:Liquid for nasal spray-Route of administration:Intranasal

Experimental: Cohort 2: Group 3- (RSVt vaccine concomitantly at 12 months)

Participants will be administered RSVt vaccine concomitantly with routine pediatric vaccines, 2 doses, at age 12 months. Vaccines administered at age 6 months: M-M-R II, VARIVAX, and Prevnar 20. Placebo will be administered non-concomitantly at 13 months of age

Pharmaceutical form:Liquid for nasal spray-Route of administration:Intranasal

Andere Namen:
  • 534

Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular

Andere Namen:
  • PREVNAR 20®

Pharmaceutical form:Liquid for nasal spray-Route of administration:Intranasal

Pharmaceutical form:Lyophilized live virus for reconstitution -Route of administration:Subcutaneous or Intramuscular

Andere Namen:
  • M-M-R® II

Pharmaceutical form:Suspension for injection-Route of administration:Subcutaneous or Intramuscular

Andere Namen:
  • VARIVAX®
Experimental: Cohort 2: Group 4- (RSVt vaccine non-concomitantly at 13 months)

Participants will be administered RSVt vaccine non-concomitantly with routine pediatric vaccines, 2 doses, at age 13 months. Vaccines administered at age 6 months: M-M-R II, VARIVAX, and Prevnar 20. Placebo will be administered concomitantly at 12 months of age

Pharmaceutical form:Liquid for nasal spray-Route of administration:Intranasal

Andere Namen:
  • 534

Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular

Andere Namen:
  • PREVNAR 20®

Pharmaceutical form:Liquid for nasal spray-Route of administration:Intranasal

Pharmaceutical form:Lyophilized live virus for reconstitution -Route of administration:Subcutaneous or Intramuscular

Andere Namen:
  • M-M-R® II

Pharmaceutical form:Suspension for injection-Route of administration:Subcutaneous or Intramuscular

Andere Namen:
  • VARIVAX®

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
RSV A serum neutralizing antibody titers at 28 days post dose 2 (D85) Groups 1 and 3
Zeitfenster: Day 85

Antibody titers at Day 85

Day 85
RSV B serum neutralizing antibody titers at 28 days post dose 2 (D85) Groups 1 and 3
Zeitfenster: Day 85

Antibody titers at Day 85

Day 85
RSV A serum neutralizing antibody titers at Day 113 Groups 2 and 4
Zeitfenster: Day 113

Antibody titers at Day 113

Day 113
RSV B serum neutralizing antibody titers at Day 113 Groups 2 and 4
Zeitfenster: Day 113

Antibody titers at Day 113

Day 113

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Anti- hepatitis B surface antigen (HBsAg) Immunoglobulin g (IgG) antibody (A)b concentrations ≥ 10 milli international units per milliliter (mIU/mL) Cohort 1
Zeitfenster: 28 days after the 6 month routine vaccinations

Antibody titers 28 days after the 6 month routine vaccinations

28 days after the 6 month routine vaccinations
Anti- polyribosylribitol phosphate (PRP) Ab concentrations ≥ 0.15 micrograms per milliliter (µg/mL) Cohort 1
Zeitfenster: 28 days after the 6 month routine vaccinations

Antibody titers 28 days after the 6 month routine vaccinations

28 days after the 6 month routine vaccinations
Anti-poliovirus types (1, 2, and 3) Ab titers ≥ 1:8 Cohort 1
Zeitfenster: 28 days after the 6 month routine vaccinations

Antibody titers 28 days after the 6 month routine vaccinations

28 days after the 6 month routine vaccinations
Anti-pertussis Ab concentrations pertussis toxin, filamentous hemagglutinin , pertactin, fimbriae (PT, FHA, PRN, FIM) Cohort 1
Zeitfenster: 28 days after the 6 month routine vaccinations

Antibody titers 28 days after the 6 month routine vaccinations

28 days after the 6 month routine vaccinations
Anti-diphtheria Ab concentrations ≥ 0.1 IU/mL Cohort 1
Zeitfenster: 28 days after the 6 month routine vaccinations

Antibody titers 28 days after the 6 month routine vaccinations

28 days after the 6 month routine vaccinations
Anti-tetanus Ab concentrations ≥ 0.1 IU/mL Cohort 1
Zeitfenster: 28 days after the 6 month routine vaccinations

Antibody titers 28 days after the 6 month routine vaccinations

28 days after the 6 month routine vaccinations
Anti-pneumococcal Ab concentrations measured by electrochemiluminescence (ECL) for serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and 33F Cohort 1
Zeitfenster: 28 days after the 6 month routine vaccinations

Antibody titers 28 days after the 6 month routine vaccinations

28 days after the 6 month routine vaccinations
Anti-measles Ab concentrations ≥ 255 mIU/mL Cohort 2
Zeitfenster: 28 days after the 12 month routine vaccinations

Antibody titers 28 days after the 12 month routine vaccinations

28 days after the 12 month routine vaccinations
Anti-mumps Ab concentrations ≥ 10 antibody units (AbU/mL) Cohort 2
Zeitfenster: 28 days after the 12 month routine vaccinations

Antibody titers 28 days after the 12 month routine vaccinations

28 days after the 12 month routine vaccinations
Anti-rubella Ab concentrations ≥ 10 IU/mL Cohort 2
Zeitfenster: 28 days after the 12 month routine vaccinations

Antibody titers 28 days after the 12 month routine vaccinations

28 days after the 12 month routine vaccinations
Anti-varicella Ab concentrations ≥ 5 glycoprotein enzyme-linked immunosorbent assay (gpELISA) units/mL Cohort 2
Zeitfenster: 28 days after the 12 month routine vaccinations

Antibody 28 days after the 12 month routine vaccinations

28 days after the 12 month routine vaccinations
Anti-pneumococcal Ab concentrations measured by ECL Cohort 2
Zeitfenster: 28 days after the 12 month routine vaccinations

Antibody titers 28 days after the 12 month routine vaccinations

28 days after the 12 month routine vaccinations
Descriptive: Anti-PRP Ab concentrations (µg/mL) Cohort 1
Zeitfenster: 28 days after the 6 month routine vaccinations

Antibody titers 28 days after the 6 month routine vaccinations

28 days after the 6 month routine vaccinations
Descriptive: Anti-diphtheria Ab concentrations (IU/mL) Cohort 1
Zeitfenster: 28 days after the 6 month routine vaccinations

Antibody titers 28 days after the 6 month routine vaccinations

28 days after the 6 month routine vaccinations
Descriptive: Anti-diphtheria Ab concentrations ≥ 0.01 IU/mL Cohort 1
Zeitfenster: 28 days after the 6 month routine vaccinations

Antibody titers 28 days after the 6 month routine vaccinations

28 days after the 6 month routine vaccinations
Descriptive: Anti-tetanus Ab concentrations (IU/mL) Cohort 1
Zeitfenster: 28 days after the 6 month routine vaccinations

Antibody titers 28 days after the 6 month routine vaccinations

28 days after the 6 month routine vaccinations
Descriptive: Anti-tetanus Ab concentrations ≥ 0.01 IU/mL Cohort 1
Zeitfenster: 28 days after the 6 month routine vaccinations

Antibody titers 28 days after the 6 month routine vaccinations

28 days after the 6 month routine vaccinations
Descriptive: Anti-HBsAg Ab concentrations (mIU/mL) Cohort 1
Zeitfenster: 28 days after the 6 month routine vaccinations

Antibody titers 28 days after the 6 month routine vaccinations

28 days after the 6 month routine vaccinations
Descriptive: Anti-HBsAg Ab concentrations ≥ 100 mIU/mL Cohort 1
Zeitfenster: 28 days after the 6 month routine vaccinations

Antibody titers 28 days after the 6 month routine vaccinations

28 days after the 6 month routine vaccinations
Descriptive: Anti-poliovirus types (1, 2, and 3) Ab titers Cohort 1
Zeitfenster: 28 days after the 6 month routine vaccinations

Antibody titers 28 days after the 6 month routine vaccinations

28 days after the 6 month routine vaccinations
Descriptive: Anti-measles Ab concentrations (mIU/mL) Cohort 2
Zeitfenster: 28 days after the 12 month routine vaccinations

Antibody titers 28 days after the 12 month routine vaccinations

28 days after the 12 month routine vaccinations
Descriptive: Anti-mumps Ab concentrations (AbU/mL) Cohort 2
Zeitfenster: 28 days after the 12 month routine vaccinations

Antibody titers 28 days after the 12 month routine vaccinations

28 days after the 12 month routine vaccinations
Descriptive: Anti-rubella Ab concentrations (IU/mL) Cohort 2
Zeitfenster: 28 days after the 12 month routine vaccinations

Antibody titers 28 days after the 12 month routine vaccinations

28 days after the 12 month routine vaccinations
Descriptive: Anti-varicella Ab concentrations (gpELISA units/mL)
Zeitfenster: 28 days after the 12 month routine vaccinations

Antibody titers 28 days after the 12 month routine vaccinations

28 days after the 12 month routine vaccinations
RSV A serum neutralizing antibody titers by baseline serostatus at Day 1 Cohort 1 and Cohort 2
Zeitfenster: Day 1

Antibody titers at Day 1

Day 1
RSV B serum neutralizing antibody titers by baseline serostatus at Day 1 Cohort 1 and Cohort 2
Zeitfenster: Day 1

Antibody titers at Day 1

Day 1
RSV A serum neutralizing antibody titers by baseline serostatus 28 days post-dose 2 1 Cohort 1 and Cohort 2
Zeitfenster: 28 days post-dose 2

Antibody titers 28 days post-dose 2

28 days post-dose 2
RSV B serum neutralizing antibody titers by baseline serostatus 28 days post-dose 2 Cohort 1 and Cohort 2
Zeitfenster: 28 days post-dose 2

Antibody titers 28 days post-dose 2

28 days post-dose 2
Presence of solicited administration site reactions within 21 days after each investigational medicinal product (IMP) administration Cohort 1 and Cohort 2
Zeitfenster: 21 days after each IMP administration

Number of participants experiencing solicited administration site reactions

21 days after each IMP administration
Presence of solicited systemic reactions within 21 days after each IMP administration Cohort 1 and Cohort 2
Zeitfenster: 21 days after each IMP administration

Number of participants experiencing solicited systemic site reactions

21 days after each IMP administration
Presence of unsolicited systemic adverse events (AEs) reported in the 30 minutes after each study intervention administration Cohort 1 and Cohort 2
Zeitfenster: Within 30 minutes after each study intervention administration

Number of participants experiencing unsolicited systemic adverse events

Within 30 minutes after each study intervention administration
Presence of unsolicited AEs within 28 days after each study intervention administration Cohort 1 and Cohort 2
Zeitfenster: Within 28 days after each study intervention administration

Number of participants experiencing unsolicited AEs

Within 28 days after each study intervention administration
Presence of medically attended adverse events (MAAEs) throughout the study Cohort 1 and Cohort 2
Zeitfenster: Throughout the study, approximately 9 months

Number of participants experiencing MAAEs

Throughout the study, approximately 9 months
Presence of serious adverse events (SAEs) throughout the study Cohort 1 and Cohort 2
Zeitfenster: Throughout the study, approximately 9 months

Number of participants experiencing SAEs

Throughout the study, approximately 9 months
Presence of adverse events of special interest (AESIs) throughout the study Cohort 1 and Cohort 2
Zeitfenster: Throughout the study, approximately 9 months

Number of participants experiencing AESIs

Throughout the study, approximately 9 months

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Publikationen und hilfreiche Links

Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

13. Mai 2024

Primärer Abschluss (Tatsächlich)

18. September 2025

Studienabschluss (Tatsächlich)

18. September 2025

Studienanmeldedaten

Zuerst eingereicht

29. April 2024

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

29. April 2024

Zuerst gepostet (Tatsächlich)

3. Mai 2024

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

5. Oktober 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

15. September 2026

Zuletzt verifiziert

1. September 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • VAD00016
  • VAD00016 (Andere Kennung: Sanofi Identifier)
  • U1111-1290-7356 (Registrierungskennung: ICTRP)
  • 2024-000262-15 (EudraCT-Nummer)

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

JA

Beschreibung des IPD-Plans

Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Ja

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .